Effects of Finasteride on Vascular Endothelial Growth Factor

REFERENCES

• MacDonagh R, Pearcy R. Quality-of-life aspects in urology-benign prostatic hyperplasia. World J Urol 1999; 17: 199–204.
   PubMed Web of Science ®Google Scholar
• Madsen FA, Bruskewitz RC. Benign prostatic hyperpla-sia: pathophysiology and pharmacological treatment. Curr Opin Nephrol Hypertens 1995; 4: 455–9.
   PubMedGoogle Scholar
• Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postopera-tive complications. A cooperative study of 13 participat-ing institutions evaluating 3,885 patients. J Urol 1989; 141: 243–7.
   Google Scholar
• Marshall S, Narayan P. Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation. J Urol 1993; 149: 1553–4.
   PubMed Web of Science ®Google Scholar
• Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report [see comments]. J Urol 1995; 154: 1779–82.
   PubMed Web of Science ®Google Scholar
• LekAs E, Johansson M, Widmark A, Bergh A, Damber JE. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997; 25: 309–14.
   Google Scholar
• Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, Puchner PJ, et al. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998; 36: 201–6.
   PubMed Web of Science ®Google Scholar
• Shabisgh A, Tanji N, D'Agati V, Burchardt M, Rubin M, Goluboff ET, et al. Early effects of castration on the vascular system of the rat ventral prostate gland. Endocrinology 1999; 140: 1920–6.
   Google Scholar
• Häggström S, Wikström P, Bergh A, Damber JE. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate 1998; 36: 71–9.
   PubMed Web of Science ®Google Scholar
• Häggström S, Lissbrant IF, Bergh A, Damber JE. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J Urol 1999; 1615: 1620–5.
   Google Scholar
• Joseph TB, Isaacs JT. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 1997; 57: 1054–7.
   PubMed Web of Science ®Google Scholar
• Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533–9.
   PubMed Web of Science ®Google Scholar
• Oesterling JE. Benign prostatic hyperplasia. Medical and minimally invasive treatment options [see comments]. N Engl J Med 1995; 332: 99–109.
   Google Scholar
• McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group [see comments]. N Engl J Med 1998; 338: 557–63.
   PubMed Web of Science ®Google Scholar
• Marks LS, Partin AW, Gormley GJ, Dorey FJ, Shery ED, Garris JB, et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia [see comments]. J Urol 1997; 157: 2171–8.
   PubMed Web of Science ®Google Scholar
• Bailey DM, Foley SJ. Microvascular anatomy in patients with recurrent haeumaturia related to prostatic hyper-trophy. BJU Int 2000; 85: 70–3.
   PubMed Web of Science ®Google Scholar
• Carlin BI, Bodner DR, Spirnak JP, Resnick MI. Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia. Prostate 1997; 31: 180–2.
   PubMed Web of Science ®Google Scholar
• Foley SJ, Soloman LZ, Wedderburn AW, Kashif KM, Summerton D, Basketter V, et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 2000; 163: 496–8.
   PubMed Web of Science ®Google Scholar
• LekAs E, Bergh A, Damber J-E. Effects of finasteride and bicalutamide on prostate blood flow in the rat. BJU Int 2000; 85: 962–5.
   Google Scholar
• Moon S-Y, Moon W-C, Choi HRC, Gi Y-JG. Finasteride inhibits angiogenesis and expression of VEGF in human BPH, abstract #1276. J Urol 1998; 159: 5.
   Google Scholar
• Lissbrant IF, Stattin P, Damber JE, Bergh A. Vascular density is a predictor of cancer-specific survival in prostate carcinoma. Prostate 1997; 33: 38–45.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991; 47: 211–18.
   Google Scholar
• Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18–32.
   PubMed Web of Science ®Google Scholar
• Connolly JM, Rose DP. Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice. J Urol 1998; 160: 932–6.
   PubMed Web of Science ®Google Scholar
• Walsh K, Sherwood RA, Dew TK, Mulvin D. Angio-genic peptides in prostatic disease. BJU Int 1999; 84: 1081–3.
   PubMed Web of Science ®Google Scholar
• Häggström S, Bergh A, Damber J-E. Vascular endothe-lial growth factor content in metastasising and non metastasising Dunning prostatic adenocarcinoma. Pros-tate 2000; 45: 42–50.
   Google Scholar
• Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 1998; 251: 287–90.
   PubMed Web of Science ®Google Scholar
• Franck-Lissbrant I, Häggström S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular re-growth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139: 451–6.
   PubMed Web of Science ®Google Scholar
• Folkman J. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence [editorial; comment]. Endocrinology 1998; 139: 441–2.
   PubMed Web of Science ®Google Scholar
• Bailey DM, Foley SJ, Wedderburn A. Effects of finasteride on microvessel density (MVD) in patients wiht recurrent haematuria related to prosatic hypertrophy (BPH), abstract #1406. J Urol 1999; 161: 4.
   Google Scholar
• Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in estab-lished human tumors follows vascular endothelial growth factor withdrawal [see comments]. J Clin Invest 1999; 103: 159–65.
   Google Scholar
• Sieber PR, Rommel FM, Huffnagle HIM, Breslin JA, Agusta VE, Harpster LE. The treatment of gross hematuria secondary to prostatic bleeding with finaster-ide. J Urol 1998; 159: 1232–3.
   PubMed Web of Science ®Google Scholar
• Miller MI, Puchner PJ. Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology 1998; 51: 237–40.
   PubMed Web of Science ®Google Scholar
• Nishi N, Oya H, Matsumoto K, Nakamura T, Miyanaka H, Wada F. Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostate. Prostate 1996; 28: 139–52.
   PubMed Web of Science ®Google Scholar
• Lopez FJ, Lahm RJ, Carrozza JP, Tofukuji M, Sellke FW, Bunting S, et al. Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am J Physiol 1997; 273: H1317–23.
   PubMed Web of Science ®Google Scholar
• Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotention. Vasc Biol 1997; 17: 2793–800.
   Google Scholar
• Hayek OR, Shabsigh A, Kaplan SA, Kiss AJ, Chen MW, Burchardt T, et al. Castration induces acute vasocon-striction of blood vessels in the rat prostate concomitant with a reduction of prostatic nitric oxide synthase activity. J Urol 1999; 162: 1527–31.
   PubMed Web of Science ®Google Scholar